Scientific Sessions 2024  /  Navigating the Mix of Meds and Lifestyle for Obesity Medicine  /  What’s the tipping point? When to initiate pharmacotherapy and can we ever stop?
Logo

American Heart Association

  106
  0

Final ID:

What’s the tipping point? When to initiate pharmacotherapy and can we ever stop?

  • Conroy, Molly  ( University of Utah , Salt Lake City , Utah , United States )
  • Wadden, Thomas  ( UNIV OF PENNSYLVANIA , Philadelphia , Pennsylvania , United States )
  • Kushner, Robert  ( Northwestern University , Chicago , Illinois , United States )
  • Jastreboff, Ania  ( UNIV OF PENNSYLVANIA , Philadelphia , Pennsylvania , United States )
  • Almandoz, Jaime  ( UT SOUTHWESTERN MEDICAL CENTER , Dallas , Texas , United States )
  • Abushamat, Layla  ( Baylor College of Medicine , Houston , Texas , United States )
    • Author Disclosures:
    Molly Conroy: No Answer | Thomas Wadden: No Answer | Robert Kushner: DO have relevant financial relationships ; Advisor:Novo Nordisk:Active (exists now) ; Advisor:Currax:Active (exists now) ; Advisor:Altimmune:Active (exists now) ; Advisor:Structure:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Advisor:Weight Watchers:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Boehringer Ingelheim:Active (exists now) | Ania Jastreboff: DO have relevant financial relationships ; Researcher:Eli Lilly:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Individual Stocks/Stock Options:Intellihealth:Active (exists now) ; Advisor:Scholar Rock:Active (exists now) ; Advisor:Structure Therapeutics:Active (exists now) ; Advisor:Zealand:Active (exists now) ; Advisor:Weight Watchers:Active (exists now) ; Advisor:Pfizer, Terns Pharmaceuticals:Active (exists now) ; Advisor:Novo Nordisk:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Boehringer Ingelheim, Biohaven:Active (exists now) ; Advisor:Amgen, AstraZeneca:Active (exists now) ; Researcher:Rhythm Pharmaceuticals:Active (exists now) ; Researcher:Boehringer Ingelheim:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) | Jaime Almandoz: DO NOT have relevant financial relationships | Layla Abushamat: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Navigating the Mix of Meds and Lifestyle for Obesity Medicine

Sunday, 11/17/2024 , 03:30PM - 04:45PM

Cardiovascular Seminar

More abstracts on this topic:
Obesity Pharmacotherapy – where are we now?

Stanford Fatima, Kosiborod Mikhail

Resources for the busy clinician: engaging your patient and addressing barriers to healthy lifestyle

Dennison Himmelfarb Cheryl, Durant Raegan, Rao Goutham

More abstracts from these authors:
Panel Discussion

Jastreboff Ania

Reducing Sedentary Behavior and Cardiometabolic Biomarkers: Results from the RESET BP Trial

Barone Gibbs Bethany, Perera Subashan, Conroy Molly, Jakicic John, Muldoon Matthew

You have to be authorized to contact abstract author. Please, Login
Not Available